Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation-Reference-Cited by-同舟云学术

Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation

Published:2015-06-04 Issue:S1 Volume:38 Page:E227-E230
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head Neck

Author:

Iakovou Ioannis¹,Goulis Dimitrios G.²,Tsinaslanidou Zinovia³,Giannoula Evanthia¹,Katsikaki Grammatiki⁴,Konstantinidis Iordanis³

Affiliation:

1. Third Department of Nuclear Medicine; Medical School, Aristotle University of Thessaloniki; Thessaloniki Greece

2. Unit of Reproductive Endocrinology; First Department of Obstetrics and Gynecology; Medical School; Aristotle University of Thessaloniki; Thessaloniki Greece

3. Second Department of Ear-Nose-Laryngology; Medical School, Aristotle University of Thessaloniki; Thessaloniki Greece

4. Medical School; Aristotle University of Thessaloniki; Thessaloniki Greece

Publisher

Wiley

Subject

Otorhinolaryngology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hed.23974/fullpdf

Reference17 articles.

1. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity;Rosário;J Nucl Med,2008

2. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation;Grewal;J Nucl Med,2009

3. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine;Silberstein;J Nucl Med,2008